>
>
>
Quraxia recognizes the evolving role of biosimilars and their potential to deliver greater value across the healthcare system. We are committed to developing biosimilar medicines that enable broad access and high-value solutions in critical areas of healthcare.
Biosimilars replicate the therapeutic outcomes of reference biologics with proven similarity in safety, efficacy, and quality, at a more accessible price point. They serve as critical enablers in broadening patient access to life-changing treatments and optimizing healthcare resources
What is a Biosimilar
A biosimilar is a biologic medicinal product that is highly similar to an already approved reference biologic in terms of structure, function, quality, safety, and efficacy, with no clinically meaningful differences between them. Unlike small-molecule generics, biosimilars are derived from living organisms and possess inherent microheterogeneity; thus, they require extensive analytical and clinical evaluation to confirm similarity rather than identity.
Our Focus on Biosimilars
Quraxia’s expertise in generic medicines naturally positions us to advance biosimilars —leveraging our foundation in generics alongside robust experience with innovative biologics for the next phase of accessible healthcare.
